7 Most Undervalued Pot Stocks To Buy According To Analysts

5. AbbVie Inc. (NYSE:ABBV)

Stock Upside Potential: 13.52%

Forward Price to Earnings Ratio (P/E): 15.43

Number of Hedge Fund Holders as of Q1 2025: 86

AbbVie Inc. (NYSE:ABBV) is one of the 7 most undervalued pot stocks to buy according to analysts. On July 3, the company provided an update to its 2025 earnings guidance to account for a pre-tax acquired in-process research and development (IPR&D) and milestones expense of $823 million in the second quarter of 2025. This expense is expected to reduce both GAAP diluted earnings per share (EPS) and adjusted non-GAAP diluted EPS by $0.42 for the second quarter. Also, the company updated its full-year 2025 adjusted diluted EPS guidance to a range of $11.67 to $11.87, incorporating the $823 million IPR&D expense.

According to the update, the $823 million expense is related to acquired IPR&D, typically incurred through collaborations, licensing agreements, and asset acquisitions. AbbVie stated that such costs are not routinely forecasted due to the uncertainty surrounding their timing and occurrence. This IPR&D expense is part of AbbVie’s broader strategy to bolster its pipeline through acquisitions and collaborations.

AbbVie Inc. (NYSE:ABBV) is a diversified healthcare company with a modest cannabis connection through its legacy drug, Marinol, a synthetic THC treatment for nausea and appetite loss. It also holds patents related to cannabis, including uses for cancer treatment, juvenile arthritis, and skin disorders.